This suggests that the high expression levels of survivin and livin in A549 cells may render the cell not very responsive to IFNγ/Smac mimetic regimen and that STAT1 together with survivin and livin may be valuable biomarkers that can predict the optimal responses to IFNγ/Smac mimetic therapy for NSCLC. The gene discussed is IFNG; the disease is non-small cell lung carcinoma.